Jordi Remon, MD, PhD, on Aumolertinib Plus Chemotherapy in EGFR-Mutated NSCLC

September 09, 2025 By The ASCO Post Staff

Jordi Remon, MD, PhD, of Gustave Roussy, was the invited discussant for the phase III ACROSS 2 study (Abstract PL02.06). Dr. Remon describes the effect of the addition of aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor, to platinum/pemetrexed chemotherapy in patients with non–small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor-suppressor gene mutations. 

Related Content